Nubeqa (Darolutamide): The 2030-2036 Generic Opportunity Window

Nubeqa (darolutamide, 300 mg oral tablets, NDA 212099) is Bayer and Orion Corporation's next-generation nonsteroidal androgen receptor antagonist approved by the U.S. FDA for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Engineered with a flexible polar bis-pyrazole architecture, darolutamide binds with high affinity to wild-type and resistance-mutant androgen receptors while exhibiting low blood-brain barrier penetration, virtually eliminating the central nervous system toxicities, cognitive impairment, and seizure liabilities associated with older antiandrogens. Nubeqa generated 2.4 billion euros ($2.7 billion USD) in 2025 global sales, surging over 57% year-over-year as Bayer's primary pharmaceutical growth driver. Nubeqa's Orange Book patent estate defines a multi-tiered generic opportunity window: 1. Core Drug Substance: U.S. Patent No. 9,657,003 (and US 8,975,254) expires on October 27, 2030 (prior to regulatory patent term extensions under 35 U.S.C. 156), claiming the darolutamide chemical entity. 2. Crystalline Form and Formulation: U.S. Patent No. 10,383,853 (and US 10,010,530) extends Orange Book protection through January 28, 2036, claiming darolutamide in its stable crystalline Form I solid-state lattice required for commercial oral tableting. Commercial generic status: 100% brand-only in the United States today; zero generic darolutamide is approved for commercial distribution or selling in the U.S. Strategic positioning among leading Indian generic manufacturers is well underway: Alembic Pharmaceuticals has secured FDA Tentative Approval for generic Darolutamide Tablets 300 mg (ANDA 218578), while major generic applicants including Hetero Labs, MSN Laboratories, Sun Pharma, and Dr. Reddy's Laboratories have submitted Paragraph IV ANDA certifications challenging Orange Book patents. SCOPE NOTE: Active Hatch-Waxman Paragraph IV patent litigation is pending in the U.S. District Court for the District of Delaware between Bayer/Orion and generic filers including Hetero, Alembic, and MSN regarding the validity and infringement of secondary crystalline form and method-of-use patents. This report takes no position on unadjudicated claims or disputed patent validity, and addresses only public, settled, and regulatory milestones.